Skip to content

Immunic, Inc.

IMUX

CIK 0001280776

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$110.46M
+3.3% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.92
+38.0% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$82.74M
Q1 Apr 2026
Cash
$186.63M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
13.62M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings